Considering the prominent role of these genes in metabolic adverse effects, we hypothesized that the genetic SREBF2 gene and INSIG2 polymorphisms might be involved in the increased risk of obesity and dyslipidemia in Thai patients treated with risperidone. Here, SREBF2 is linked to obesity due to melanocortin 4 receptor deficiency.